A new breakthrough from the University of Saskatchewan may lead to a shorter calving season for beef producers. Cetrorelix, a hormone drug commonly used in human IVF treatments, has shown promise for use in cattle reproduction. Dr. Jaswant Singh, along with graduate students Dylan Farmer and Carlos Leonardi, discovered the drug’s efficacy in synchronizing ovulation in cows, leading to simultaneous pregnancies and potentially shorter calving periods.
The innovative drug could offer a more efficient method for managing cattle breeding, reducing labor costs and improving animal outcomes. Garner Deobald, a beef rancher and marketing manager at BoviGen Genetic Services, sees the potential benefits of Cetrorelix for enhancing breeding practices. If proven effective, it could revolutionize artificial insemination methods, offering better genetic control and calf predictability.
The University of Saskatchewan has applied for a patent for Cetrorelix and aims to collaborate with pharmaceutical companies to bring it to market. Dr. Singh is optimistic about the drug’s prospects and envisions widespread adoption in the farming community. With regulatory hurdles largely overcome, the focus now is on refining the application of Cetrorelix for animal use, with the goal of benefiting livestock producers worldwide.